FDA Clears Updated DWI Software for Portable MRI Neuroimaging Device
The new software for the Swoop® Portable MR Imaging system reportedly enhances the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences by 42 percent in comparison to the previous software.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new software for the Swoop® Portable MR Imaging device that may significantly enhance the quality of diffusion-weighted magnetic resonance imaging (MRI) for neurocritical patients.
The new software offers a 42 percent increase in the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences, according to Hyperfine, the manufacturer of the device. The company noted other benefits of the software include additional compensation for subtle patient movements and more uniform imaging for DWI sequences.
Emphasizing the key role DWI imaging plays in facilitating prompt diagnosis of an array of neurological conditions as well as the monitoring of stroke progression, Hyperfine said the updated software will provide a significant advance in care for high-risk populations.
“With this latest software, Swoop system images provide increasingly valuable diagnostic images that can aid clinicians in caring for neurocritical patients,” noted Edward Knopp, M.D., the senior medical director with Hyperfine.
Hyperfine received an FDA 510(k) clearance earlier this month for the device’s updated brain imaging software. The company said the updated DWI software will be available in March 2023.
(Editor’s note: For related content, see “Emerging Deep Learning System May Enhance MRI Assessment of Intracranial Tumors” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
